Keywords: Amylin, Eli Lilly, Exenatide, Byetta, Bydureon

Amylin diabetes drug exenatide deal with Eli Lilly terminated, with $1.45 billion settlement to Lilly

Article | 09 November 2011

Print This

Shares of US biotech firm Amylin Pharmaceuticals fell 8.4% to $10.01 in pre-market trading yesterday, when it was revealed it had agreed ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in